Collegeville, PA, United States of America

Michael T Rudd

This inventor holds 36 USPTO granted patents and 5 published patent applications, plus 1 CIPO patent and 28 EPO patents, primarily in Orexin Receptor Agonists. Top assignees: Merck Sharp + Dohme Corp., Merck Sharp & Dohme LLC, Msd R&d (China) Co., Ltd.. Active years: 2008-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael T Rudd. Retrieved from https://idiyas.com/inventor/michael-t-rudd

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 36 (Patent Applications = 5)

% Patents Active = 94.4

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 28 (Patent Applications = 25)

Average Co-Inventor Count = 6.8

ph-index = 4

Forward Citations = 101(Granted Patents)

Company Filing History:

30 out of 2,405

Merck Sharp + Dohme Corp.

patents

5 out of 70

Merck Sharp & Dohme LLC

patents

3 out of 10

Msd R&d (China) Co., Ltd.

Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa

Merck Msd (r&d) China Co., Ltd.

patent

where one patent can have more than one assignee

Years Active: 2008-2026

Loading Chart...

Areas of Expertise:

Orexin Receptor Agonists

Liver X Receptor Beta Agonists

HCV NS3 Protease Inhibitors

Pyrrolidine Derivatives

Bicycloheptane Compounds

Allosteric Modulators

Therapeutic Compounds

Macrocyclic Compounds

Aryl Ether Derivatives

Pyrazole Derivatives

Piperidine Derivatives

Quinoline Derivatives

36 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12760005 - Bicycloheptane pyrrolidine orexin receptor agonists (2026-10-13),

2. 12692262 - Substituted ureas as orexin receptor agonists (2026-07-28),

3. 12686690 - Macrocyclic urea orexin receptor agonists (2026-07-21),

4. 12552767 - 3-heteroaryl pyrrolidine and piperidine orexin receptor agonists (2026-02-17),

5. 12497362 - Cyclopentapyrrole orexin receptor agonists (2025-12-16),

6. 12331018 - Pyrrolidine orexin receptor agonists (2025-06-17),

7. 12312332 - Heteroaryl pyrrolidine and piperidine orexin receptor agonists (2025-05-27),

8. 11826375 - Phosphinic amide prodrugs of tenofovir (2023-11-28),

9. 11680060 - Bicycloheptane pyrrolidine orexin receptor agonists (2023-06-20),

10. 11655216 - Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use (2023-05-23),

11. 11339156 - 3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor (2022-05-24),

12. 11149036 - 3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor (2021-10-19),

13. 11098029 - 5-alkyl pyrrolidine orexin receptor agonists (2021-08-24),

14. 10981902 - 5-(pyridin-3-yl)oxazole allosteric modulators of the M4 muscarinic acetylcholine receptor (2021-04-20),

15. 10961215 - N-aryl and N-heteroaryl piperidine derivatives as liver X receptor beta agonists, compositions, and their use (2021-03-30),

Sure, here is an article about inventor Michael T Rudd:

Title: Unveiling the Inventive Spirit of Michael T Rudd from Collegeville, PA

Introduction:

Michael T Rudd, a prolific inventor hailing from Collegeville, PA, has made significant contributions to the field of pharmaceuticals and neurological research. With an impressive portfolio of 29 patents under his belt, Rudd's innovative work has left a lasting impact on the medical industry.

Latest Patents:

Rudd's recent patents include groundbreaking inventions such as "Phosphinic amide prodrugs of tenofovir" and "Bicycloheptane pyrrolidine orexin receptor agonists." These patents highlight his pioneering work in the inhibition of HIV reverse transcriptase and the potential treatment of neurological and psychiatric disorders.

Career Highlights:

Having worked with esteemed companies like Merck Sharp & Dohme Corporation and MSD R&D (China) Co., Ltd., Rudd has been at the forefront of cutting-edge research and development in the pharmaceutical sector. His expertise and dedication have been instrumental in bringing innovative solutions to the market.

Collaborations:

Throughout his career, Rudd has collaborated with industry stalwarts such as Nigel J Liverton and John A McCauley. These collaborations have not only fueled his creative endeavors but have also paved the way for transformative advancements in the field of medicine.

Conclusion:

In conclusion, Michael T Rudd's exceptional talent and unwavering commitment to innovation have solidified his place as a trailblazing inventor in the realms of pharmaceuticals and neurological research. His remarkable contributions continue to shape the landscape of medical science, offering hope and healing to countless individuals worldwide.

Profile summary based on public USPTO records.